RecruitingNCT06161428
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer
Optical Guided Sentinel Node Biopsy for Staging of Vulvar Cancer ( SENTIVUC II)
Sponsor
Rigshospitalet, Denmark
Enrollment
100 participants
Start Date
May 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of the study is to evaluate the feasibility of applying the SLN mapping technique in combination with FDG-PET/CT imaging in women with vulva cancer tumour size \>4 cm, multifocal tumors and local recurrences.
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria1
- Patients with vulva cancer, tumor \> 4 cm, multifocal tumor, or local recurrences in vulva
Exclusion Criteria4
- Previous external irradiation of the vulva or groins
- Former sentinel node or inguinal lymphadenectomy in the relevant groin
- Known allergy to ICG or iodine
- Patient is in active treatment for other cancer and/or disseminated disease
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06161428
Related Trials
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
NCT0488992459 locations
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
NCT056862263 locations
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT074332839 locations
3D Printed Custom Applicators for HDR BT (DISCO)
NCT064324781 location
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
NCT030175736 locations